title: The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib.
abstract: Imatinib mesylate has become the gold standard front-line treatment of chronic myelogenous leukemia through its ability to inhibit ABL tyrosine kinase. Resistance to this inhibition may occur. We investigated the role of the K247R polymorphism in persistent sensitivity.
authors.forename: Franck Emmanuel
authors.initials: FE
authors.lastname: Nicolini
authors.forename: Kaddour
authors.initials: K
authors.lastname: Chabane
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Cayuela
authors.forename: Philippe
authors.initials: P
authors.lastname: Rousselot
authors.forename: Xavier
authors.initials: X
authors.lastname: Thomas
authors.forename: Sandrine
authors.initials: S
authors.lastname: Hayette
mesh_terms: D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D020125:Mutation, Missense; D010597:Pharmacogenetics; D010879:Piperazines / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D016315:Proto-Oncogene Proteins c-abl / Q000235:genetics*; D011743:Pyrimidines / Q000494:pharmacology*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016315:Proto-Oncogene Proteins c-abl